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Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and usually lethal fibrotic lung 
disease with as yet unknown etiology and treatment. IPF lungs have a definitive gene expression 
signature, but the role of microRNAs in IPF has not been studied. MicroRNA genes are short, 
non-coding RNAs that function as post-transcriptional gene regulators. We hypothesized that 
microRNAs are differentially expressed in IPF and play a role in the pathogenesis of the disease.  
The microRNA expression profile of IPF lungs was characterized using microRNA 
microarrays. We identified 18 significantly decreased and 28 significantly increased microRNAs 
in samples obtained from patients with IPF compared to controls. Promoter analysis of the 
decreased microRNAs recognized a SMAD3 binding site in the promoter of let-7d. SMAD3 
binding and responsiveness to TGF-β of the let-7d promoter were confirmed by SMAD3 ChIP, 
EMSA, luciferase assays and reduced expression of let-7d in response to TGF-β. In situ 
hybridization confirmed a significant reduction in let-7d expression in IPF lungs and localized it 
to alveolar epithelial cells in the control lungs. To study the role of let-7d, we determined the 
consequences of loss of function of let-7d by inhibiting its expression in lung epithelial cells. In-
vitro inhibition of let-7d caused increases in epithelial mesenchymal transition (EMT) markers 
N-cadherin (CDH2), vimentin (VIM), alpha-smooth muscle actin (ACTA2) and high mobility 
group AT-hook 2 (HMGA2). HMGA2 is a proven let-7d target that was increased in IPF lungs 
and localized to alveolar epithelial cells. We reproduced our in vitro results in vi vo. In mice, 
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intratracheal administration of a let-7d inhibitor caused alveolar septal thickening, increases in 
collagen, ACTA2 and CDH2 and decreases in the epithelial markers, CDH1 and ZO1. We 
colocalized the mesenchymal markers FSP1 and ACTA2 with the epithelial marker SPC, 
indicative of EMT. 
Our results indicate a definitive role for microRNAs in IPF. The downregulation of let-7d 
in IPF and the pro-fibrotic effects of this downregulation in vitro and in vivo suggest a key 
regulatory role for this microRNA in preventing lung fibrosis. Deciphering their mechanism of 
action of microRNAs has great public health significance. It would add new insight into the 
pathophysiology of the disease and aid in reducing the mortality by development of therapeutic 
interventions. 
 vi 
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1.0  INTRODUCTION 
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown etiology and no proven treatment. 
Though there is a distinct gene expression signature of this disease, the microRNA profile has 
not been studied. MicroRNA profiles are altered in different types of cancers and also in benign 
diseases. We hypothesized that there exists a unique microRNA profile for IPF. Differentially 
expressed microRNAs will possibly be targeting some disease-relevant genes. The aim of this 
study was to identify these microRNAs and determine their role in the pathogenesis of IPF.  
1.1 PUBLIC HEALTH SIGNIFICANCE 
 
Idiopathic pulmonary fibrosis is a chronic, progressive and usually lethal interstitial lung disease 
[1]. The incidence of IPF in US is 16.3 per 100,000 persons with a median survival of 2.5-3 
years from diagnosis [2]. The etiology and molecular mechanisms underlying the lung phenotype 
in IPF are largely unknown. A number of risk factors like smoking, infectious agents, drugs and 
genetic predisposition are thought to contribute to disease development [3, 4]. Currently, there is 
no known cure for this devastating disease. Clinical management focuses mainly on supportive 
care and in a few cases lung transplant. Though the gene expression of IPF has been studied [5-
13], the contribution of changed expression of microRNAs to IPF is not known. MicroRNAs add 
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a new level of gene regulation to the already existing complex cellular networks. Deciphering 
their mechanism of action would add new insight into the pathophysiology of the disease and aid 
in therapeutic interventions. 
1.2 IDIOPATHIC PULMONARY FIBROSIS 
The 2002 international consensus classification of the idiopathic interstitial pneumonias (IIPs) 
recommended by the American Thoracic Society and European Respiratory Society [4] 
recognizes seven distinct clinicopathologic entities of which IPF is the most frequent. An 
international consensus statement regarding the diagnosis of IPF has been outlined [3]. The 
major criteria include (a) exclusion of other known causes of interstitial lung diseases, (b) 
abnormal pulmonary function tests indicative of restriction and abnormal gas exchange, (c) 
Bibasilar reticular abnormalities with minimal ground glass opacities on HRCT scans and (d) 
bronchoalveolar lavage does not support any other diagnosis. The minor criteria include (a) over 
50 years, (b) gradual onset of shortness of breath, (c) symptoms persisting for more than 3 
months and (d) bibasilar crackles on auscultation. All major criteria and at least 3 minor criteria 
are necessary for an accurate diagnosis of IPF. Histological characteristics of IPF lungs include 
increase in extracellular matrix deposition, honeycombing of the lung and the presence of 
myofibroblast foci. 
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Figure 1. Histolgical characteristics of IPF, (a) Honeycomb lung, (b) Fibroblast focus. 
 
Studying the disease in an animal model plays an important role in determining the 
pathobiology. Modeling IPF in an animal model is difficult since the etiology and the natural 
history of the disease is as yet uncertain and no single agent has been able to mimic IPF in 
animals. Common methods include radiation damage, instillation of bleomycin, silica or asbestos 
or gene transfer of fibrogenic cytokines. The most common method of inducing experimental 
pulmonary fibrosis is bleomycin instillation. Bleomycin is an anti-neoplastic drug with lung 
fibrosis being one of its side effects. The bleomycin-inactivating enzyme, bleomycin hydrolase, 
is present at low levels in lungs. Hence the lungs are more prone to bleomycin-induced fibrosis 
[14]. Following intratracheal instillation of bleomycin, there is an initial rise in inflammatory 
cytokines followed by an elevation in profibrotic markers which peaks around day 14 [15]. 
Histological hallmarks of IPF are seen in lungs of bleomycin-treated mice [16]. Bleomycin-
induced fibrosis is partially reversible over time [17]. The slow and irreversible progression of 
IPF is not reproduced in the bleomycin model. 
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1.2.1 Genetic Associations of IPF 
The vast majority of IPF cases occur sporadically, a few cases being familial. Approximately one 
of every 50 patients with IPF has an affected first-degree family member [18, 19]. The clinical 
presentation of familial and sporadic IPF is similar, though familial IPF manifests earlier. 
Pulmonary fibrosis is also associated with a number of well-defined genetic disorders, including 
Hermansky-Pudlak Syndrome, Gaucher Disease and Familial Hypocalciuric Hypercalcemia [20-
23]. This indicates some mode of inheritance of genes responsible for the development of 
pulmonary fibrosis.  
Specific gene mutations are also observed in some patients. One such gene, surfactant 
protein C (SFTPC), codes for a hydrophobic membrane protein produced by alveolar type II 
epithelial cells. It works with other surfactant proteins (A, B, D) to reduce surface tension in the 
aqueous alveolar space and allows gas exchange. The mutations results in protein misfolding and 
consequent epithelial cell injury [24, 25].  A genetic mutation in surfactant protein A2 has now 
been identified in some familial cases of IPF.  
Telomere reverse transcriptase (hTERT) is another gene which has an association with 
IPF. Telomeres contain multiple repeats of the TTAGGG sequence at the ends of chromosomes. 
Some of these repeat sequences are lost with each cell division. The telomerase enzyme encoded 
by hTERT, mediates addition of TTAGGG to replace those lost during cell division. Without the 
proper telomerase activity, telomeres will shorten to the point that cells will fail to divide [26]. 
Tsakiri et al ., conducted genome-wide linkage studies and identified a mutation in hTERT that 
co-segregated with idiopathic interstitial pneumonias in two families [27]. Those individuals 
with heterozygous mutations in hTERT or hTERC had shorter telomere lengths compared to 
controls [27, 28]. Short dysfunctional telomeres lead to cell death which manifests as organ 
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failure in tissues of high turnover. The bronchoalveolar epithelium is constantly being replaced 
and relies on local progenitor cells to be replaced which are limited by short telomeres. Armanios 
et al . propose that the fibrotic lesions and remodeling are a result of loss of alveolar epithelial 
cells [28]. Fortunately, these genetic mutations are known to have low penetrance suggesting that 
factors other than genetics contribute to the disease pathogenesis even in familial cases.  
1.2.2 Pathophysiology of IPF 
 The initial model for the pathology suggested that chronic inflammation was the underlying 
cause of IPF [29, 30]. But since immunosuppressive drugs do not change the prognosis and 
measures of tissue inflammation correlate poorly to the outcome of the disease, an alternate 
hypothesis of epithelial injury was proposed. 
Alveoli are lined by alveolar type I and type II cells. The type II cells cover about 5% of 
the surface. They secrete surfactant into the alveoli and differentiate into type I cells when the 
latter are injured. The type I cells cover about 95% of the alveolar surface and facilitate gas 
exchange. In IPF however, this normal mechanism of type I cell replacement is lost [31, 32]. The 
alveolar cells either undergo apoptosis or epithelial mesenchymal transition (EMT). The nature 
of the epithelial injury is unknown though it has been speculated that viral infections [33] or 
oxidative stress [34, 35] may play a role. The injured alveolar epithelium serves as a major 
source of TGF-β1 and many other cytokines including endothelin-1 and tumor necrosis factor-
α [36−38] independent of pro-inflammatory mediators [39]. These profibrotic cytokines 
influence the neighbouring fibroblasts which in turn secrete reactive oxygen species, Fas and 
angiotensin-II further inducing epithelial cell injury and apoptosis [40]. Thus each cell type 
influences the survival and proliferation of the other. The alveolar epithelium also has an 
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intrinsic capacity to respond to TGF-β1 stimulation through differential expression of TGF-β1 
receptor subtypes [41]. The epithelial cells overlying the fibroblastic foci are hyperplastic and 
dysplastic having an abnormal morphology and altered gene expression [42, 43]. Persistent 
injury to epithelial cells leading to the loss of the basement membrane integrity to an extent 
where normal repair cannot take place is essential for all the subsequent fibrotic events [44]. 
Matrix metalloproteinases (MMPs) are also secreted by injured epithelial cells. MMPs are 
capable of degrading various components of connective tissue matrices are believed to play a 
significant role in remodelling after parenchymal damage. MMPs can participate in the fibrotic 
process at two stages- at the injury stage by degrading the basement membrane and extracellular 
matrix constituents; and secondly at the "attempted repair" stage where the MMPs may 
contribute to increased accumulation of extracellular matrix components such as collagens, 
fibronectin, elastin and proteoglycans [45]. 
Increased apoptosis of type II cells has been demonstrated in areas that appear 
histologically normal [46] and in epithelial cells that near the myofibroblasts [47]. Increase in 
proapoptotic protein expression and a decrease in antiapoptotic proteins has been reported [48]. 
Mice developed lung fibrosis after they were administered aerosolized anti-Fas antibody [49]. It 
has recently been shown that activated myofibroblasts produce extracellular reactive oxygen 
species that is sufficient to induce apoptosis in adjacent epithelial cells [40]. However, the 
adjacent fibroblasts and myofibroblasts show little evidence of apoptosis [47, 48, 50].  Human 
lung fibroblasts express increased amounts of inhibitors of apoptosis such as XIAP and FLIP 
[51]. 
Another cytokine implicated in the pathogenesis of IPF is endothelin-1 (ET-1). ET-1 is 
the principal effector of the many profibrotic roles of TGF-β such as the differentiation of 
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fibroblasts to myofibroblasts [52], the production of altered ECM components [53], the 
inhibition of ECM degradation [52, 53] and in EMT [54]. Alveolar macrophages spontaneously 
secrete ET-1 in IPF when compared with control subjects [55, 56]. Serum and bronchoalveolar 
lavage from IPF patients has increased amounts of ET-1 [57, 58]. Immunohistochemical analysis 
of lung biopsies from IPF patients demonstrated increased staining for ET-1 especially in areas 
of active tissue remodeling [55]. Bleomycin-induced pulmonary fibrosis in the rat results in 
increased ET-1 and its receptor expression [59-61]. Also, transgenic mice that overexpress 
human pre–proET-1 and ET-1 transcriptional elements spontaneously develop progressive 
pulmonary fibrosis [62]. 
1.2.3 Gene expression studies of IPF 
High throughput gene expression profiling studies have been conducted to determine the 
characteristic gene expression signature of IPF lungs. Gene expression patterns are distinct in 
fibrotic and non-fibrotic lungs [5-13] irrespective of the microarray platform used [6, 11, 12, 63]. 
Genes that encode proteins involved in extracellular matrix formation, degradation, and signaling 
such as matrix metalloproteinases, collagens I and III, osteopontin are increased in fibrotic lungs. 
Genes that encode immunoglobulins, complement, and some chemokines are also up-regulated 
in fibrotic lungs. Among the down-regulated genes is caveolin-1 [64] and advanced 
glycosylation end products-specific receptor (AGER) [65]. 
Recently, the gene expression data [6, 8, 11] has been reanalyzed [66]. The analysis 
revealed that IPF lungs were significantly enriched with genes associated with lung 
development. The up-regulated development-relevant genes included several members of 
transcription factor families such as the Sry-related high mobility group box and forkhead box, 
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and genes related to the Wnt/β-catenin pathway and many EMT-related genes. These pathways 
that play an essential role during embryological development are inactivated in adults but may be 
transiently expressed during wound repair. Aberrant activation of these pathways in adults may 
be associated with the development of IPF.  
1.2.4 Origin and role of the myofibroblast 
The myofibroblast plays a central role in the pathogenesis of IPF. Many myofibroblasts 
aggregate to form the fibroblastic focus, a characteristic histological hallmark of IPF. Increased 
numbers of these foci is associated with disease progression and a worse prognosis [67]. 
Examination of tissue sections suggest that fibrotic foci are isolated lesions, but Cool et al . 
demonstrated that the foci are a form of a highly complex, interconnected and continuous fibrotic 
reticulum [68]. The myofibroblast has a spindle-shaped morphology, intracytoplasmic stress 
fibers, and a contractile phenotype. It expresses the mesenchymal marker, α-smooth muscle actin 
and produces collagen [69]. Although myofibroblasts are a part of normal repair mechanisms, 
their persistence beyond a period of normal repair is associated with extracellular matrix 
deposition and structural remodeling [70]. Epithelial cells overlying the fibroblastic foci are 
hyperplastic and dysplastic with abnormal morphology and gene expression patterns [42, 43]. 
These cells serve as a major source of TGF-β and many other cytokines including endothelin-1 
and TNF-α during lung injury [36, 38]. The increase of myofibroblasts in injured lungs has 
several deleterious effects, contributing to the abnormal alveolar re-epithelialization, and 
excessive and disordered deposition of extracellular matrix in the lung parenchyma. It has been 
demonstrated that IPF fibroblasts produce angiotensin peptides able to induce epithelial cell 
death in vitro, which also probably occurs in v ivo [47, 71]. In addition, IPF myofibroblasts 
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synthesize gelatinases A and B, two matrix metalloproteinases that degrade basement membrane 
molecules, contributing to the failure of an orderly repair of alveolar type I epithelial cells and 
enhancing the migration of fibroblasts/myofibroblasts into the alveolar spaces [72]. A number of 
hypotheses have been proposed regarding the origin of the myofibroblast. 
The first theory proposes that resident lung fibroblasts respond to many stimuli and 
differentiate into myofibroblasts [70]. TGF-β induces transdifferentiation of fibroblasts in vitro 
through SMAD3 [73]. 
Another potential source of myofibroblasts is circulating mesenchymal progenitors or 
fibrocytes [74]. These are spindle-shaped cells that are likely bone marrow derived. They 
migrate to sites of tissue injury and can differentiate into fibroblast-like cells [75]. Fibrocytes 
express the common leukocyte antigen CD45, the hematopoietic stem cell antigen CD34 and 
mesenchymal markers such as collagen, fibronectin, alpha-smooth muscle actin and prolyl-4-
hydroxylase. Transplantation of green fluorescent protein-positive bone marrow into wild type 
mice and subsequent induction of fibrosis in these mice by irradiation showed that about 20-50% 
of the cells in the fibrotic areas were bone marrow-derived [76]. Direkze et al [77] demonstrated 
multiple organ engraftments by bone marrow-derived fibroblasts and myofibroblasts in mice 
following radiation injury. Patients with IPF have an increased number of circulating fibrocytes 
[78]. Andersson-Sjoland et al  demonstrated the presence of fibrocytes in lungs of IPF patients 
[79]. A subsequent study showed that fibrocytes were significantly elevated in stable IPF with a 
further increase in acute exacerbations of the disease and can be used as a clinical marker for 
disease progression [80]. 
Recently it has been proposed that alveolar epithelial cells (AEC) undergo epithelial-
mesenchymal transition (EMT) to form fibroblasts. It has also been proposed that ongoing AEC 
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injury and retarded wound repair may be central to the pathogenesis of IPF. The authors showed 
that epithelial injury and blunted epithelial repair is sufficient to promote the pulmonary fibrotic 
process [81]. The exact nature of the epithelial injury is unknown, but viral infection may play a 
role. Depending on the nature of injury and extent of disruption of the basement membrane, 
injured AECs may undergo apoptosis, proliferate and differentiate into type I AEC to effect re-
epithelialization or may undergo EMT and hence contribute directly to fibrosis. Kim et al. 
demonstrated EMT in the lungs of mice [82]. Mice expressing β-galactosidase (β-gal) 
exclusively in lung epithelial cells were generated and the mice were administered adenoviral 
active TGF-β1. β-gal-positive cells expressing mesenchymal markers accumulated within 3 
weeks of in vivo TGF-β1 expression. In a subsequent publication they showed that α3 integrin 
was required for β-catenin phosphorylation at tyrosine residue 654, formation of the pY654–β-
catenin/pSmad2 complex, and initiation of EMT [83]. Tanjore et al. [84] showed using cell fate 
reporter mice that approximately one-third of S100A4-positive fibroblasts were derived from 
lung epithelium and one-fifth of S100A4-positive fibroblasts were derived from bone marrow 2 
weeks after bleomycin administration. 
1.2.5 Signaling pathways in IPF 
Progressive pulmonary fibrosis is a disorder of dysregulated cytokine production which 
subsequently leads to activation of different signaling pathways. A number of different pathways 
are involved in the pathogenesis of IPF, the most important being the TGF-β signaling pathway 
and the Wnt-β-catenin pathway.  
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1.2.5.1 TGF-β signaling pathway 
TGF-β inhibits epithelial growth, acting as a tumor suppressor but it also promotes carcinoma 
progression and metastasis. TGF-β binds to the type II receptor which phosphorylates the type I 
receptor. This causes phosphorylation of SMAD2 and SMAD3 which alongwith the common 
mediator SMAD4 are translocated to the nucleus and results on transcriptional activation or 
inhibition of target genes [85].   
Many studies prove that TGF-β is the main cytokine in the pathogenesis of IPF. Increased 
expression of TGF-β mRNA and protein has been detected in the interstitial matrix and 
myofibroblasts found in areas of active extracellular matrix deposition in fibrotic foci of IPF 
patients [37, 86-90]. Alveolar macrophages secrete TGF-β in both humans and bleomycin-
induced mouse model of fibrosis [88, 90]. 
Adenoviral-vector mediated gene transfer of TGF-β into rats induced histological changes 
similar to those seen in IPF patient lungs. There is increased extracellular matrix formation, 
destruction of the normal lung architecture and the characteristic honeycombing [91, 92]. 
Nuclear SMAD3 increased in bleomycin-treated mice lungs [93] whereas SMAD3 knockout 
mice were protected against bleomycin induced pulmonary fibrosis [94-96]. Mice were protected 
from bleomycin-induced lung fibrosis when exogenous SMAD7, an inhibitor of TGF-β signaling 
was administered [97]. Also, administration of exogenous TGF-β induced EMT in rat alveolar 
Type II cells, which was blocked by adenoviral-induced SMAD7 [98].  
1.2.5.2 Wnt signaling pathway 
The best characterized Wnt signaling pathway is the β-catenin-dependent, or canonical, Wnt 
signaling pathway [99, 100]. In the absence of active Wnt ligands, β-catenin is constitutively 
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phosphorylated by its interaction with axin, adenomatosis polyposis coli (APC), and glycogen 
synthase kinase (Gsk-3β), and subsequently degraded. In the presence of Wnt ligands, two 
distinct membrane receptors, the frizzled (Fzd) or the low density lipoprotein receptor-related 
proteins (Lrp) 5 and 6, are activated upon ligand binding. This leads to phosphorylation of Lrp6 
by Gsk-3β and casein kinase γ in its cytoplasmic region, which leads to the recruitment of axin. 
Subsequently, β-catenin phosphorylation is attenuated, its degradation inhibited, and 
accumulated β-catenin undergoes nuclear translocation, where it regulates target gene expression 
through interaction with members of the T-cell-specific transcription factor/lymphoid enhancer-
binding factor (Tcf/Lef) family. 
In IPF, Chilosi et al . [101] showed that nuclear β-catenin immunoreactivity localized to 
proliferative bronchiolar lesions and fibroblastic foci. β-catenin signaling can play a role in 
experimental EMT [101] suggesting that the aberrant nuclearization of β-catenin in bronchiolar 
lesions could promote EMT in the diseased lung. Matrix metalloproteinase-7 (matrilysin) is an 
important target gene of β-catenin [102]. Microarray screens have also revealed an increased 
expression of Wnt target genes, such as MMP7, or secreted frizzled-related protein (Sfrp) 2 in 
IPF [8, 12, 103]. Konigshoff et al. [104] demonstrate that the WNT/β-catenin signaling pathway 
is activated in the epithelium during lung fibrosis. The WNT target gene, WNT1-inducible 
signaling protein 1 (WISP1), was highly upregulated in experimental and idiopathic lung 
fibrosis. 
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1.3 EPITHELIAL-MESENCHYMAL TRANSITION 
Epithelial mesenchymal transition is a process in which a polarized epithelial cell undergoes 
multiple changes which cause it to assume a mesenchymal cell phenotype, increased migratory 
capacity, resistance to apoptosis and increased production of extracellular matrix components 
[105]. EMT is said to be complete when the underlying basement membrane is degraded and the 
mesenchymal cell migrates away from the original epithelial layer. Many molecular processes 
like expression of cell-surface proteins, activation of certain transcription factors, reorganization 
of cytoskeletal proteins, production of extracellular matrix degrading enzymes and expression of 
certain microRNAs are initiated during EMT. EMT is seen during embryogenesis, organ 
development, wound healing, organ fibrosis and cancer. Immune privilege might be necessary 
for EMT associated with development but inflammation and epigenetics is necessary for fibrosis 
and carcinogenesis. 
EMT has been characterized into three functional groups in a recent meeting in 2007 in 
Poland and subsequently in 2008 at Cold Spring Harbor Laboratories [106-109].  
Type 1: During development, EMT plays a critical role in generating the first set of 
mesenchymal cells known as the primary mesenchyme. Subsequently, as diverse types of tissues 
are formed, the primary mesenchyme gives rise to secondary epithelia by a reversal of the 
process i.e. by mesenchymal epithelial transition. 
Type 2: This EMT is a part of a repair process in which fibroblasts are formed to repair 
the tissue following injury or inflammation. This ceases once repair is achieved and the cause is 
removed. But in the presence of continued injury or inflammation, type 2 EMT continue the 
reparative process which ultimately leads to organ destruction by fibrosis. 
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Type 3: This occurs in epithelial cells which differ genetically and epigenetically from 
untransformed epithelial cells. These changes mainly affect oncogenes and tumor suppressors. 
The cells generated by type 3 EMT have the capacity to invade into the surrounding tissues, 
enter the blood circulation and ultimately metastasize into distant tissues. These metastatic 
nodules have secondary epithelia suggesting the capability of reversal of the EMT process. 
While the three classes of EMT are distinct biological processes, a common set of 
elements seem to underlie these seemingly diverse programs [106-108]. Type 2 EMT shall be 
discussed in greater details as it is relevant to the topic being studied. 
Type 2 EMT is found to be associated with fibrosis of the kidney, lung, liver and 
intestine. It is mediated by inflammatory cells and fibroblasts that release various inflammatory 
signals and components of the extracellular matrix such as collagens, laminins and elastins. 
Fibroblast specific protein 1 (FSP1), alpha smooth muscle actin, desmin, discoidin domain 
receptor tyrosine kinase 2 (DDR2) and collagen 1 are markers used to characterize mesenchymal 
cells produced by EMT [107]. Cells undergoing the process of EMT express these mesenchymal 
markers along with the epithelial markers cytokeratin, E-cadherin and zona occludens. EMT in 
the kidney has been studied more extensively than in the lung. Inflammatory injury to the mouse 
kidney results in recruitment of macrophages and activated resident fibroblasts that accumulate 
at the site of injury and release growth factors such as TGF-β, PDGF, EGF and FGF2 [110]. 
These cells also release chemokines and matrix metalloproteases (MMPs) like MMP2, MMP3 
and MMP9. Contact of epithelial cells with the molecules leads to degradation of the basement 
membrane [110] and subsequently the epithelial cells migrate towards the interstitium under the 
gradient of growth factors and other chemoattractants. Fibroblasts produced by EMT express 
fibroblast-specific protein 1 which is regulated by a promoter element called fibroblast 
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transcription site-1 (FTS-1). The proteins CArG box-binding factor-A (CBF-A) and KRAB-
associated protein 1 (KAP-1) bind this site. The FTS-1 site is also present in promoters of Twist, 
Snai1, E-cadherin, β-catenin, ZO-1, vimentin, α-smooth muscle actin. Venkov et al. showed that 
the formation of the CBF-A/KAP-1/FTS-1 complex is sufficient for the induction of FSP1 and a 
novel proximal activator of EMT [111]. 
 TGF-β has been to shown to elicit EMT through HMGA2 [112]. HMGA2 (High 
Mobility Group AT-hook 2) or HMGI-C is a part of a family of nuclear factors that bind AT-rich 
DNA sequences in the minor groove and contribute to transcriptional regulation by altering the 
chromatin structure and organizing nucleoprotein complexes such as enhanceosomes [113-115]. 
Thuault et al. [112] showed that TGF-β directly targets HMGA2 through the SMAD 
transcription factors, mainly SMAD4 thereby increasing HMGA2 transcription.  
 
Figure 2. Mechanistic model of EMT. 
 
An important event in EMT is the loss of E-cadherin which maintains cell-cell adhesion. 
SNAI1, SNAI2, ZEB1, ZEB2, TWIST, and E47 have all been identified as transcriptional 
repressors of E-cadherin [116]. HMGA2 regulates Snai1, Snai2, Twist and Id2, all key players of 
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EMT. TGF-β, through HMGA2, increases the expression of Snai1, Snai 2 and  Twist but 
decreases that of Id2. The AT-hook domains of HMGA2 bind to the Snai1 promoter DNA and 
also interact with the MH1 and MH2 domains of SMADs, leading to transcriptional activation of 
Snai1 gene [117]. Snai1 regulates the expression of Snai2, ZEB1 and ZEB2 but not Twist. Id2 
and Id3 form complexes with basic helix-loop-helix transcription factors such as E47 and inhibit 
the process of EMT [118, 119]. 
1.3.1 MicroRNAs and EMT 
Recently, microRNAs have been shown to be a part of the processes involved in EMT. The 
microRNAs miR-200 and miR-205 inhibit the repressors of E-cadherin expression, ZEB1 and 
ZEB2 and help to maintain the epithelial cell phenotype [120-123]. This has been demonstrated 
in breast cancer. These miRNAs can hence be classified as tumor suppressors. In contrast, miR-
21 [124, 125], mir-155 [126] and the miR-17~92 cluster [127] are upregulated in many cancers 
and facilitate TGF-β-induced EMT. MiR-21 is found in TGF-β-induced EMT in human 
keratinocytes, a model of epithelial cell plasticity for epidermal injury and skin carcinogenesis 
[128]. MiR-21 is abundantly expressed and associated with carcinogenesis. It targeted two tumor 
suppressors, tropomyosin 1 (TPM1) and programmed cell death-4 (PDCD4) to modulate the cell 
proliferation, microfilament organization, and anchorage-independent growth [129, 130]. The 
knockdown of miR-155 suppressed TGF-β-induced epithelial-mesenchymal transition (EMT) 
and tight junction dissolution, as well as cell migration and invasion. Further, the ectopic 
expression of miR-155 reduced its target RhoA, and disrupted tight junction formation [126]. 
Pottier et al . demonstrated that miR-155 targeted keratinocyte growth factor and the levels of 
miR-155 correlated with the degree of lung fibrosis in a mouse model [131]. 
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1.3.2 Mesenchymal epithelial transition (MET) 
The reverse process of EMT is MET in which the mesenchymal cells obtain epithelial cell 
characteristics. MET is seen during organ development when the mesenchymal cells generated 
as a result of EMT subsequently generate secondary epithelia. In tumors, the migratory cancer 
cells generate secondary metastatic nodules which exhibit an epithelial phenotype. Korpal et al. 
demonstrated that overexpression of the miR-200 family members either individually or as 
clusters in NMuMG cells hindered EMT by enhancing E-cadherin expression through direct 
targeting of ZEB1 and ZEB2 [121]. 
1.4 SMALL RNAS 
At least three classes of small RNAs are encoded in the human genome, based on their 
biogenesis mechanism and the type of Argonaute protein involved: microRNAs (miRNAs), endo 
genous small interfering RNAs (endo‑siRNAs or esiRNAs) and Piwi‑interacting RNAs 
(piRNAs). MicroRNAs are expressed in all cell types whereas endo-siRNAs and piRNAs are 
expressed mainly in germ cells and contribute to germline development [132]. 
1.4.1 MicroRNAs 
MicroRNAs were first discovered in  C. elegans [133-138]. They are single-stranded RNAs of 
about 18-24 nucleotides in length processed from endogenous hairpin-shaped transcripts. 
MiRNAs are present within the introns of genes (intronic miRNAs) or may be in between genes 
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(intergenic). They are transcribed by either RNA polymerase II [139] or RNA polymerase III 
[140] into primary miRNA transcripts (pri-miRNA). These pri-miRNAs have a cap and a poly A 
tail which are hallmarks of polymerase II transcription. Lee et al. showed that their transcription 
is sensitive to treatment with the polymerase II inhibitor α-amanitin, and polymerase II binds to 
promoter sequences upstream of the miR-23a/miR-27a/miR-24-2 cluster [139]. In contrast, 
miRNAs encoded by the largest human miRNA cluster, C19MC, are transcribed by polymerase 
III [140]. Expression of selected miRNAs is under the control of transcription factors, for 
example c-Myc or p53 [141, 142], or depends on the methylation of their promoter sequences 
[143]. In addition, it has been shown that each miRNA located in the same genomic cluster can 
be transcribed and regulated independently. At present the microRNA database 
(microrna.sanger.ac.uk) contains 721 microRNAs. 
MiRNA biogenesis [144, 145] takes place in the presence of two RNase enzymes, Drosha 
and Dicer. Both proteins have two tandem RNase III domains and a double-stranded RNA-
binding domain (dsRBD). At the first step of miRNA biogenesis, the primary transcript which is 
generated upon RNA polymerase II transcription is cleaved at the stem of the hairpin structure 
by an RNase III-type protein Drosha to release the precursor form (pre-miRNA). Drosha acts in 
the presence of a cofactor DiGeorge syndrome critical region 8 (DGCR8) in humans and Pasha 
in Drosophila melanogaster and Caenorhabditis elegans.  Drosha and DGCR8 together form a 
large complex called the Microprocessor complex which is ~650 kDa in humans. A pri-miRNA 
normally has a stem of about 33 bp, a terminal loop and flanking single stranded segments. 
DGCR8 interacts with these segments and the stem and assists Drosha in cleaving the transcript 
at ~ 11 bp away from the ssRNA-dsRNA junction. Two RNase III domains interact with each 
other to form a dimer. The first cuts the 3` strand whereas the second cuts the 5` strand forming a 
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2 nucleotide 3` overhang. The pre-miRNAs are transported to the cytoplasm in the presence of 
exportin 5 alongwith the cofactor Ran-GTPAse. Exportin 5 recognizes the >14bp dsRNA stem 
and the short 3` overhangs on either side. In the cytoplasm, the pre-miRNAs are cleaved by 
Dicer near their terminal loop to release ~22 nt miRNA duplexes. Dicer interacts with TAR 
RNA-binding protein (TRBP) and PACT which contribute to the formation of the RNA-induced 
silencing complex (RISC complex) along with Argonaute (Ago). The miRNA duplex is loaded 
onto and Ago protein to form the RISC. One strand remains as the mature miRNA (guide strand 
or miRNA) whereas the other strand (passenger strand or miRNA *) is degraded. Generally the 
strand with relatively unstable base pairs at the 5` end forms the mature miRNA. Some hairpins 
produce miRNAs from both strands.   
For intronic miRNAs, cropping by Drosha and intron splicing are highly co-ordinated 
processes. Drosha processing takes place after the transcript is bound to the spliceosome 
complex but before the intron is spliced out. Sometimes, small RNAs are embedded in short 
introns and hence do not need Drosha for their processing. Following splicing, the intron forms a 
hairpin-shaped structure which is the precursor miRNA. Precursors formed in this manner are 
called mirtrons.  
1.4.2 Let-7 family of microRNAs 
The lethal-7 (let-7) gene was initially discovered as an essential developmental gene in C. 
elegans [136] and as one of the first miRNAs. The let-7 family of miRNAs is often present in 
multiple copies [146] in a genome and is highly conserved across species [147].  
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Table 1. let-7 family in humans. 
let-7 member chromosome strand position cluster 
let-7a-1 9 + intergenic let-7f-1, let-7d 
let-7a-2 11 - intergenic miR-100 
let-7a-3 22 + intergenic let-7b 
let-7b 22 + intergenic let-7a-3 
let-7c 21 + intronic (C21orf34) miR-99a 
let-7d 9 + intergenic let-7f-1, let-7a-1 
let-7e 19 + intergenic miR-99b, miR-125a 
let-7f-1 9 + intergenic let-7a-1, let-7d 
let-7f-2 X - intronic(HUWE1) miR-98 
let-7g 3 - intronic(WDR82) - 
let-7i 12 + intergenic - 
 
Biological functions for let-7 include the regulation of stem-cell differentiation in C. 
elegans [136], neuromusculature development and adult behaviors in flies [148, 149], limb 
development in mouse [150], and cell proliferation and differentiation [148, 151-154]. Many let-
7-family members function as tumor suppressors in a variety of cancers [155]. Whereas let-7-
family of miRNAs have a distinct temporal pattern of expression in vertebrate development [152, 
156, 157], a direct role for let-7 in vertebrate development has not been shown due to the 
difficulty associated with knocking out multiple let-7-family members in the same animal and 
the possible redundancy associated with such large families. In another study, let-7 was found to 
be expressed in breast-stem-cell progenitors as they differentiate [158]. In addition, reduced 
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expression of multiple let-7 members have been found to be associated with human cancers 
[155] and with cancer stem cells [151], leading to the strong suggestion that, as in C. elegans, 
let-7 genes function to promote terminal differentiation in development and function as tumor 
suppressors. 
In vertebrates, the let-7 family has many more members than in C. elegans and D. 
melanogaster [133], including multiple forms that seem to be modified post-transcriptionally 
[159]. Interestingly, not only are the sequences and timing of expression of let-7 and many of its 
family members conserved across species [133, 147] but the genomic organization and clustering 
of miRNAs for many of the let-7 members is also conserved [160]. The selective pressure to 
conserve these clusters further underscores the importance of these genes and the need to 
maintain their correct expression patterns both spatially and temporally. In higher organisms, the 
levels of let-7 rise during embryogenesis [150], and pri-let-7a and pri-let-7e and mature let-7a, 
let-7c and let-7e are upregulated during mouse brain development [152]. Recent studies have 
found that a homolog of one of the C. elegans heterochronic genes, LIN28, is directly involved 
in the post-transcriptional regulation of the let-7 family of miRNAs in mammalian cells [161, 
162]. LIN28 binds to the loop structure of what will become the precursor hairpin and prevents 
Drosha processing of pri-let-7 in the nucleus [161]. LIN28 also regulates the subsequent step by 
preventing the pre-let-7 from being turned into mature let-7 too early by binding to the pre-let-7 
stem and preventing Dicer processing in the cytoplasm [163]. Lin28 interacts with pre-let-7 and 
mediates the terminal uridylation of pre-let-7 [164]. The uridylated pre-let-7 is resistant to Dicer 
processing due to its elongated tail and susceptible to degradation. 
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2.0  MATERIALS AND METHODS 
2.1 SAMPLE COLLECTION 
Lung tissue samples for microarray analysis were obtained through the University of Pittsburgh 
Health Sciences Tissue Bank as previously described [6, 7]. 10 samples were obtained from 
surgical remnants of biopsies or lungs explanted from patients with IPF who underwent 
pulmonary transplant and 10 control normal lung tissues obtained from the disease free margins 
with normal histology of lung cancer resection specimens. The morphologic diagnosis of IPF 
was based on typical microscopic findings consistent with usual interstitial pneumonia [165]. All 
patients fulfilled the diagnostic criteria for IPF outlined by the American Thoracic Society and 
European Respiratory Society [3]. All studies were approved by the Institutional Review Board 
at the University of Pittsburgh. 
2.2 CELL CULTURE 
A549 cells (CCL-185, American Type Culture Collection, Manassas, VA) and RLE-6TN cells 
(CRL-2300, ATCC) were grown in F12K medium (Invitrogen, Carlsbad, CA) with 2 mM L-
glutamine and 10% fetal bovine serum. Primary normal bronchial epithelial cells (NHBE) 
(Lonza, Switzerland) were grown with the basal medium and BulletKit supplied by the company. 
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Cells were incubated at 37 °C in a humidified chamber supplemented with 5% CO2. All 
experiments were done in 80% confluent cells. Before TGF-β, cells were serum starved 
overnight and treated 3 ng/ml TGF-β (R&D, Minneapolis, MN) 
2.3 RNA ISOLATION 
Total RNA from tissues and cells was isolated using the miRNeasy Mini kit (Qiagen, Valencia, 
CA) according to the manufacturer’s instructions. The quantity of the RNA was determined by 
optical density, measured at 260nm by Nanodrop spectrophotometer. RNA quality was measured 
using the RNA 6000 Nano kit and the small RNA kit on the Agilent Bioanalyzer 2100. 
2.4 MICROARRAYS 
MicroRNA profiling was carried out using the Agilent Human microRNA Microarray. These 
microarrays have an 8 x 15K design with 470 microRNAs based on Release 9.1 of Sanger 
miRBASE. The manufacturer’s instructions were followed in the labeling and hybridization of 
the RNA. Briefly, 100 ng of total RNA was dephosphorylated using calf intestine alkaline 
phosphatase (GE Healthcare, Piscataway, NJ), denatured with DMSO, and labeled with pCp-Cy3 
using T4 RNA ligase (New England Biolabs, Ipswich, MA) at 16°C for 2h. The labeled RNA 
was purified using Micro Bio-spin 6 columns and hybridized onto the Agilent microRNA 
microarrays at 55°C for 20h. The arrays were washed with Gene Expression Wash Buffers 1 and 
2 (Agilent) and scanned using the Agilent Microarray Scanner. The scanned images were 
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processed by Agilent’s Feature Extraction software version 9.5.3. The gene expression 
microarrays have been previously described [13]. Briefly, lung samples were lysed in ice cold 
Trizol and total RNA was extracted and used as a template for double stranded cDNA synthesis.   
Labeling was performed using the Agilent Low RNA Input Linear Amplification Kit PLUS, 
(One-Color) (Agilent Technologies, Santa Clara, CA). Briefly, double stranded cDNA synthesis 
was performed using an oligo(dT) primer containing a T7 RNA polymerase promoter site. The 
cDNA was used as a template to generate Cy3 labeled cRNA that was used for hybridization. 
After purification and fragmentation aliquots of each sample were hybridized to Agilent Whole 
Human Genome 4 X 44K multi pack arrays (Agilent Technologies, Santa Clara, CA). After 
hybridization, each array was sequentially washed and scanned (Agilent DNA microarray 
scanner). Data files were normalized using cyclic LOESS. Differentially expressed genes were 
identified using Significant Analysis of Microarrays (SAM).  
2.5 STATISTICAL ANALYSIS 
MicroRNA microarray data was log2 transformed, normalized to the mean of each array and a 
Wilcoxon rank-sum test was used to identify those microRNAs that were differentially expressed 
(p-value < 0.05) between IPF and control lungs; each microRNA has 3-4 unique probes on the 
array. Only microRNAs whose mean values for each probes had an expression value >95% of 
the negative controls in at least one condition were considered for statistical analysis. Data 
visualization was accomplished using Genomica (http://genomica.weizmann.ac.il) [166] and 
Spotfire Decision Site 8.0 (Spotfire Inc., Göteborg, Sweden, http://spotfire.tibco.com). For qRT-
PCR, statistical significance was determined by Student’s t-test using p<0.05. In s itu 
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hybridizations were analyzed by student t-test and Mann-Whitney test to compare let-7d positive 
AECs/mm2 between IPF and control lung samples. 
2.6 QUANTITATIVE RT-PCR 
TaqMan MicroRNA assays (ABI, Foster City, CA) were used to determine the relative 
expression levels of microRNAs. For RT reactions, 50 ng of total RNA was used in each 15 µl 
reaction. The conditions for the RT reaction were: 16 °C for 30 min; 42 °C for 30 min; 85 °C for 
5 min; and then held on 4 °C. The cDNA was diluted 1:14 and 1.33 µl of the diluted cDNA was 
used with the TaqMan primers in the PCR reaction. The conditions for the PCR were: 95 °C for 
10 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min in the ABI 7300 real-time 
PCR system. The results were analyzed by the ∆∆Ct method using RNU43 control RNA for 
normalizing human microRNAs and snoRNA55 for mouse microRNAs. Fold change was 
calculated taking the mean of the controls as the baseline. TaqMan gene expression assays (ABI) 
were used to determine the relative expression levels of HMGA2, CDH2, VIM, ACTA2, CDH1, 
ZO1 and COL1A. 500 ng of RNA was reverse transcribed using the SuperScript First-Strand 
Synthesis System for RT-PCR (Invitrogen) in a total reaction volume of 20 µl, the cDNA diluted 
1:5 and 3 µl of this cDNA was used in a total volume of 31 µl for the PCR. PCR conditions were 
as follows: 12 min at 95°C, followed by 40 cycles with 15 s at 95°C and 1 min at 60°C in the 
ABI 7300 real-time PCR system. The results were analyzed by the ∆∆Ct method and GUSB was 
used for normalization. Fold change was calculated taking the mean of the controls as the 
baseline. 
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2.7 MICRORNA PROMOTER ANALYSIS 
Genomic coordinates of all differentially expressed microRNAs between IPF and control lungs 
and the coordinates of their murine orthologues were obtained from the UCSC Genome Browser 
[167]. The 1kb sequence upstream of the intergenic microRNAs and the 1kb sequence upstream 
of the host gene for the intronic microRNAs were collected. The host gene promoter sequence 
was used for intronic microRNAs because previous reports have shown that the microRNA and 
host gene are co-transcribed and share the same promoter region [168]. SMAD3 and SMAD4 
binding site prediction was carried out with the FOOTER algorithm using default parameters 
[169]. 
2.8 CHROMATIN IMMUNOPRECIPITATION 
The ChIP protocol was performed according to the published protocol from the Young 
laboratory [170]. A549 cells were grown to 5x107 – 1x108 cells per analysis condition. Cells 
were either untreated (control) or stimulated with 2 ng/mL TGF-β for 30 minutes. Chromatin 
cross-linking was performed by adding 1/10 volume of freshly prepared 11% formaldehyde 
solution for 15 minutes at room temperature. The cross-linking reaction was then quenched by 
adding 1/20 volume of 2.5M glycine. Cells were rinsed twice with PBS, collected with a silicon 
scraper, flash frozen in liquid nitrogen, and stored at -80°C until use. Upon thawing, cells were 
resuspended in a lysis buffer and sonicated at 4°C to solubilize cellular components and shear 
crosslinked chromatin. The cell lysate was incubated overnight at 4°C with 100 μl of Dynal 
Protein G magnetic beads that had been preincubated with 10 μg of either antiflag (mock IP) or 
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anti-SMAD3 antibodies (Millipore, Billerica, MA). Protein G magnetic beads were washed five 
times with RIPA buffer and one time with TE buffer containing 50 mM NaCl. Cross-linked 
promoter fragment/transcription factor complexes were eluted from the beads by heating at 65°C 
with vortexing at 2 minute intervals for 15 minutes. Crosslinking was reversed by incubation at 
65°C overnight. Recovered promoter fragments were treated with RNaseA, proteinase K 
digestion, and purified by phenol:chloroform:isoamyl alcohol extraction/ethanol precipitation. 
Gene-specific PCR was performed on a portion of the purified recovered nucleic acid (35 cycles) 
to verify the presence of the upstream sequence of pre-hsa-let-7d. The primers used for gene 
specific PCR are: let-7d forward: 5' - CAC TTA AAC CCA GGA GGC AGA GGT T - 3' and 
let-7d reverse: 5' - ACC ACG TAT TAC TGG AGT CGC TGA - 3'; 
2.9 ELECTROMOBILITY SHIFT ASSAY 
Cultured A549 lung alveolar epithelial carcinoma cells at 60-70% confluence were treated with 2 
ng/mL recombinant human TGFβ1 (R&D Systems) for 60 minutes. Nuclear proteins were 
isolated using a standard rapid micropreparation technique described previously [171]. The 
supernatant was reserved and snap frozen in liquid nitrogen as the nuclear protein fraction. 
Nuclear extracts and recombinant full length SMAD3 protein (Santa Cruz Biotechnology, Santa 
Cruz, CA) were incubated with 5’-end Cyanine-5 labeled probe and/or non-labeled competitor 
oligonucleotide for 20 minutes at room temperature in a binding buffer consisting of 20% 
glycerol, 5 mM MgCl2, 2.5 mM EDTA, 25 mM DTT, 200 mM NaCl, 50 mM Tris HCl pH 7.6, 
and 0.25 mg/mL poly(dI-dC). The complementary oligonucleotides (5' - 
GATAATTAAATGTTAAAAGTCAGC - 3', 5' - GCTGACTTTTAACATTTAATTATC 
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- 3') were synthesized by Integrated DNA Technologies (Coralville, IA), and consisted of a 
sequence upstream of the predicted SMAD3/let7d binding site (GGCTGAGTA). Additionally, a 
supershift assay was performed by incubating nuclear extract with 0.1 µl rabbit monoclonal 
antibody [EP568Y] to SMAD3 (Abcam, Cambridge, MA) or 1.0 µl mouse monoclonal [4A3] to 
peroxiredoxin 6 as a control (Abcam) prior to incubating with the target oligonucleotide. The 
protein/DNA complexes were run on a 6% native polyacrylamide gel and visualized on a 
Typhoon imaging and documentation system using Cyanine-5 dye excitation and fluorescence 
settings. 
2.10 LUCIFERASE REPORTER ASSAYS 
Luciferase assays were performed on A459 cells transfected with pGL4.17 (Promega, Madisson, 
WI) constructs containing -1600 to +87 base pair region of let-7d at the 5' end of the reporter 
gene. The eight base pair Smad3 site deletion (GCTGAGTA) plasmid was constructed using 
Quick Change mutagenesis kit (Stratagene, La Jolla, CA). The sequence of the deleted plasmid 
was confirmed by nucleotide sequencing from both strands. For TGF-β treatment A459 cells 
were grown to 80% confluence and stimulated for two hours at 10ng/ml. Reporter DNA was 
transfected using Lipofectamine 2000 (Invitrogen) at 1:1 ratio for 4h and cell growth continued 
for another 16h. Luciferase activity was determined using dual-reporter assay system (Promega). 
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2.11 TISSUE MICROARRAY (TMA) CONSTRUCTION 
The tissue microarrays were previously described [172]. A total of 60 tissue samples consisting 
of 40 IPF and 20 control tissues derived from the normal part of lungs removed for benign 
lesions were snap-frozen and stored at -70°C. Specimens were fixed in cold-ethanol for 16 h and 
then embedded in paraffin. Hematoxylin and eosin (H&E) -stained sections were made from 
each block to define representative fibrotic and inflammatory lesion regions. Areas of interest 
were identified in H&E stained slides by a conventional microscope (Olympus BX-50). Tissue 
cylinders with a diameter of 1.5 mm were punched from selected areas of each “donor” block 
using a thin-wall stainless tube from a precision instrument (TMA-100, Chemicon, USA) and 
were transferred by a solid stainless stylet into defined array coordinates in a 45 * 20 mm new 
recipient paraffin block. The tissue microarray blocks were constructed in three copies (each 
containing one sample from a different region of all lesions). One sample was taken from the 
center and two samples from different peripheral areas. Ultimately, we constructed three tissue 
microarray blocks comprising of 80 tissue elements each. Each tissue element in the array was 
1.5 mm in diameter and spacing between two adjacent elements was 0.1mm. After the TMA 
construction 5 μm sections for in situ hybridization analysis were cut from the “donor” blocks 
and were transferred to glass slides using an adhesive-coated tap sectioning system. 
2.12 IN SITU HYBRIDIZATION 
Lung tissues were obtained from the tissue bank of two different pathology centers (University 
Hospital of Alexandroupolis, Greece and the Veterans Administration Hospital, N.M.T.S, 
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Athens, Greece). The tissues were fixed in 10% formalin, paraffin-embedded and after the TMA 
construction samples were cut into 5 μm thick serial sections and were transferred to glass slides 
using an adhesive-coated tap sectioning system. The Rembrandt Universal RISH & AP 
Detection Kit (Invitrogen) was used for the in situ hybridization, with slight modifications. 
Briefly, the paraffin sections were dewaxed in xylene for 2 x 5 min, soaked in 100% ethanol. 
Then the paraffin sections were soaked in 75% ethanol and after in wash buffer solution so the 
tissue can retain its initial pH. The sections were then treated with proteolytic solution supplied 
in the kit for 20 min at 37°C. Excess proteolytic solution was discarded and the slides were 
dehydrated in 75%, 95% and 100% ethanol for 1 min each and then air-dried. Denaturation and 
hybridization was done overnight at 37°C with 20 nM 5`-digoxigenin labeled miRCURY LNA 
detection probe (Exiqon, Denmark) diluted in hybridization buffer (50% Formamide, 5xSSC, 
0.1% Tween, 9.2mM citric acid for adjustment to pH 6, 50ug/ml heparin, 500ug/ml yeast RNA). 
The slides were washed in TBS buffer for 3 x 1 min. Slides were transferred onto a 37°C heating 
block or slide warmer and 2-3 drops of alkaline phosphatase conjugate were applied to each 
specimen. Slides were then incubated for 30 minutes at 37°C. Excess detection reagent was 
tapped off and slides were washed in TBS buffer. Slides were then soaked in three changes of 
TBS buffer for 1 minute each and then transferred into a container with distilled or deionized 
water and soaked for 1 additional minute. They were then taken out; excess of water was wiped 
off and dried around the edges using a lint-free cloth. Sections were then transferred onto a 37°C 
heating block and 2-3 drops of NBT/BCIP substrate were applied to each specimen. Then slides 
were incubated in the dark for 5-15 minutes at 37°C (color development was examined every 5 
minutes with a light microscope) and removed from the heating block. They were then washed 
three times for 1 minute in changes of distilled or deionized water. The slides were 
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counterstained using Nuclear Fast Red. 2-3 drops of counterstain were applied to each slide (with 
hematoxylin for 10 sec) and rinsed in distilled water for 3 min. Slides were then incubated for 15 
sec, excess of counterstain was tapped off and then they were washed briefly in distilled or 
deionized water. Images were acquired by using the high-resolution DUET, BioView scanning 
system for CISH, morphology applications. 
2.13 CISH SEMIQUANTITATIVE IMAGE ANALYSIS 
The number of let-7d positive alveolar epithelial cells (AECs)/mm2 in 5 fields per case was 
counted by two independent pathologists - observers using the high-resolution DUET, BioView 
scanning system for CISH morphology and immunocytochemistry applications, at x100 
magnification. Independent t-test and Mann-Whitney test were used to compare let-7d positive 
AECs/mm2 between IPF and control lung samples. 
2.14 IMMUNOHISTOCHEMISTRY 
Tissue sections were treated as previously described [72]. Anti- HMGA2 rabbit polyclonal 
antibody (4 µg/ml) (Abcam) was applied and samples were incubated at 4°C overnight. A 
secondary biotinylated anti-immunoglobulin followed by horseradish peroxidase-conjugated 
streptavidin (BioGenex, San Ramon, CA) was used according to manufacturer’s instructions. 3-
amino-9-ethyl-carbazole (BioGenex) in acetate buffer containing 0.05% H2O2 was used as 
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substrate. The sections were counterstained with hematoxylin. The primary antibody was 
replaced by non-immune serum for negative control slides.  
Mouse lung tissue was fixed and inflated with PROTOCOL SafeFix (Fisher Scientific, 
Waltham, MA). Tissue sections were deparaffinized and rehydrated using xylene and sequential 
ethanol rinses, endogenous peroxidase activity blocked with methanol and hydrogen peroxide, 
antigen retrieval done by heating the slides in sodium citrate buffer pH 6.0 at 95 °C for 30 min 
followed by blocking in 5% goat serum for 30 min. The sections were incubated with the 
appropriate antibody for 1 hour at room temperature. Following two 5 min washes in TBS, the 
sections were incubated in the secondary antibody for 30 min, washed twice for 5 min in TBS, 
incubated for 30 min with RTU Vectastain Elite ABC Reagent (Vector Laboratories), washed in 
TBS stained with DAB Substrate kit (Vector Laboratories) according to the manufacturer’s 
instructions, counterstained with hematoxylin and mounted in Vectashield hardset mounting 
medium (Vector Laboratories). The number of ACTA2 positive alveolar epithelial cells (AECs) 
in 10 fields per slide was counted by two independent pathologists at x60 magnification. T-test 
was used to compare ACTA2 positive AECs between saline and antagomir-treated lung sections. 
2.15 TRANSFECTION 
A549 cells, RLE-6TN cells and NHBE cells were plated in 6-well plates at 50% confluence. 
A549 cells and RLE-6TN cells were plated in F12K medium containing 10% fetal bovine serum 
while NHBE cells were plated in the basal medium supplemented with the bullet kit supplied by 
Lonza. After the cells were adherent, the medium was changed to Opti-MEM I reduced serum 
medium (Invitrogen). Transfection of hsa-let-7d inhibitor, pre-let-7d and their corresponding 
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negative controls (Ambion, Austin, TX) was carried out at 50 nM using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. RNA was isolated 24h and 48h post 
transfection. 
2.16 IMMUNOBLOTTING 
Immunoblotting was used to detect the protein expression in RLE-6TN cells grown in 6-well 
plates were transfected either with the scrambled oligonucleotide or let-7d inhibitor. The cells 
were washed in ice-cold phosphate-buffered saline (PBS) and lysed at 4º C with a solution 
containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM PMSF, 1mM EDTA, 5µg/ml 
aprotinin, 5µg/ml leupeptin, 1% Triton x-100, 1% sodium deoxycholate and 0.1% SDS. The 
soluble cell lysate was centrifuged at 16000 x g for 15 min and the supernatant was transferred to 
a clean microcentrifuge tube. Protein concentrations were measured using the BCA Protein 
Assay Kit (Pierce, Rockford, IL). 10 µg of the lysate was resolved by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto an Immobilon-P 
membrane (Millipore Corporation, Billerica, MA). After blocking with 3% bovine serum 
albumin for 1h, the membrane was incubated overnight with the desired antibody at 4º C. 
Following three 10 min washes with tris-buffered saline Tween-20 (TBST), the membranes were 
incubated with the appropriate secondary antibody for 1h at room temperature. Target proteins 
were observed using the Western Lightning Chemiluminescence Reagent Plus Kit (Perkin Elmer 
Life Sciences, Boston, MA) according to the manufacturer’s instructions. Equal protein loading 
was assessed by stripping the membranes with 0.1M glycine, pH 2.0 and reprobing with 
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antibodies against β-actin (Sigma) or lamin A/C. Densitometric analysis was performed using the 
ImageJ software (National Institute of Health).  
2.17 IMMUNOFLUORESCENCE 
A549 cells were plated on cover slips. Cells were starved for 24 hours by the removal of serum 
and transfected with 50 nM anti-let7d for 48 hours. Cover slips were removed, and fixed in 2% 
paraformaldehyde (Sigma) for 40 minutes. Permeabilization of cells was carried out by using 
0.1% Triton X in PBS for 40 minutes, with three washes in PBS each for five minutes followed 
by blocking with 0.3% BSA and 5% goat serum in PBS for 60 minutes, and incubated with anti-
cytokeratin, anti-vimentin, anti-N-cadherin, or anti-alpha-smooth muscle actin (all from Abcam 
Inc., Cambridge, MA) in 0.5% BSA in PBS for 60 minutes. Following three washes with 0.5% 
BSA in PBS (5 minutes each), coverslips were incubated with the appropriate secondary 
antibody (Invitrogen, Carlsbad, CA) for one hour at 37°C. After staining, cover slips were 
washed with 0.1% Triton in PBS for 2 times 5 minutes each followed by three washes with PBS 
5 minutes each. Coverslips were inverted onto slides and mounted in Vectashield anti-fade 
medium that contained DAPI for nuclei staining (Vector Laboratories, Burlingame, CA) to 
prevent photobleaching. Slides were examined using a Leica TCS-SP2 laser scanning confocal 
microscope equipped with appropriate lasers for simultaneous imaging of up to four 
fluorophores.  
Lung tissue from mice was frozen into OCT blocks and sectioned. The frozen sections 
were fixed in ice cold acetone for 15 min. After washing the sections twice for 2 min each in 
PBS, avidin-biotin blocking was performed using the Avidin/Biotin Blocking kit (Vector 
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Laboratories) according to the manufacturer’s instructions. The sections were blocked for 30 min 
in a blocking buffer consisting of 5% goat serum and 3% bovine serum albumin in PBS. The 
sections were then incubated in the desired primary antibody for 1h, washed for 5 min in PBS 
and incubated in the appropriate secondary antibody for 30 min. After washing for 5 min in PBS, 
the sections were incubated in Fluorescein Avidin DCS for 10 min followed by another wash of 
5 min in PBS. This procedure was repeated for the second antibody but incubated with Texas 
Red Avidin DCS for 10 min. The nuclei were stained with 4'-6-Diamidino-2-phenylindole 
(DAPI) for 1 min, washed in PBS for 5 min and mounted using VECTASHIELD HardSet 
Mounting medium (Vector Laboratories). Slides were examined using an Olympus Fluoview 
1000 confocal microscope equipped with appropriate lasers. Colocalization was quantified using 
MetaMorph software (Molecular Devices, CA). 
2.18 SYNTHESIS OF ANTAGOMIR 
The design of the let-7d antagomir was adapted from Krutzfeldt et al [173]. The single-stranded 
RNA 5` -aacuaugcaaccuacuaccucu- 3` was custom synthesized from Dharmacon, Lafayette, CO. 
The sequence of the oligonucleotide was complementary to that of mmu-let-7d. All bases had 2’-
O-methyl modifications, the first two bases and the last four bases had phoshorothioate linkages 
and a cholesterol molecule was conjugated at the 3’ end. The sequence of the scrambled control 
was 5` -aaccauguaaacuacuacaucu- 3`. 
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2.19 ANIMALS 
6-12 week old C57BL/6 mice were purchased from the Jackson Laboratory and housed under 
pathogen-free conditions. The studies were approved by the Animal Care and Use Committee at 
the University of Pittsburgh. In the shorter protocol, 4 mice were treated either with 10 mg/kg 
body weight let-7d antagomir administered intratracheally in 50 µl or an equal volume of saline. 
In the extended protocol, mice were administered the antagomir on days 1, 2, 3, 8, 9, 10, 15, 16, 
17 and sacrificed on day 18. Two control mice were administered the same volume of saline in 
each of the three groups. There were 7 mice in each group when the scrambled control was used. 
2.20 BLEOMYCIN ADMINISTRATION 
0.0375 U of bleomycin (Hospira, IL) was administered intratracheally in 50 µl of 0.9% saline. 
Mice were sacrificed after 14 days and RNA isolated from the lungs. 
2.21 MASSON’S TRICHROME STAINING 
Sections were stained as per the established protocol [174] by the University of Pittsburgh 
Transplantation Institute Core Facility. 10 images per slide were obtained. Airways and blood 
vessels were avoided so as to not introduce any bias in the quantitation. The total tissue per 
section was quantified as the area in pixels. The total blue stain was also measured as area in 
pixels. MetaMorph software (Molecular Devices) was used to perform the analysis. 
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3.0  RESULTS 
3.1 MICRORNAS ARE DIFFERENTIALLY EXPRESSED IN IPF AND CONTROL 
LUNGS 
Total RNA from 10 control and 10 IPF lungs was isolated, labeled with Cy3 dye and hybridized 
on Agilent microRNA microarrays. Fig. 3 shows the heatmap generated from the microRNA 
microarray data. Every column represents a patient and every row represents a microRNA. 
Yellow represents upregulated and purple represents downregulated microRNAs. Expression of 
the microRNAs showing no difference between the two groups being compared is grey. The 
heatmap on the left represents the global microRNA expression. The heatmap on the right 
represents statistically significant (p-value < 0.05) differentially expressed microRNAs. Let-7d, 
miR-30 family, miR-26 family and several members of the miR-17~92 cluster are 
downregulated in IPF. The entire microRNA microarray dataset has been deposited in the Gene 
Expression Omnibus (GSE13316). 
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Figure 3. microRNAs are differentially expressed in IPF. 
 
To validate our microarray results, we performed qRT-PCR of 14 microRNAs that 
significantly decreased according to our microarray data. The relative changes of microRNA 
expression assayed using microarray analysis and qRT-PCR were consistent. Validation of the 
microarray results confirmed that let-7d, miR-26 family, miR-30 family and the miR-17~92 
cluster were indeed significantly (p<0.05) downregulated (Fig. 4). 
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Figure 4. qRT-PCR verification of the microarray results of reduced let-7d, miR-26 and miR-30 
families and the miR-17~92 cluster in IPF. 
 
Though the bleomycin model cannot be promoted as an experimental equivalent of IPF, it 
is the most common method of inducing experimental pulmonary fibrosis. We assessed whether 
let-7d expression was similar in mice treated with bleomycin (Fig. 5). Let-7d expression is 
significantly decreased at day 14 post-bleomycin administration which falls within the “fibrotic 
phase”. 
 
Figure 5. let-7d expression in mice treated with bleomycin. 
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Since the gene expression profile of IPF lungs is enriched with genes from developmental 
pathways [66], we quantified these validated down-regulated miRNAs in fetal lung tissue. Most 
of the microRNAs downregulated in IPF were also downregulated in fetal lung tissues as 
assessed by real-time PCR (Fig. 6). There were 10 tissue samples in each set. Yellow denotes an 
increase and purple denotes a decrease in expression. 
 
Figure 6. MicroRNA expression in control, IPF and fetal tissues. 
 
It can be concluded that let-7d expression is decreased in IPF, fetal lungs and in the 
bleomycin model of lung fibrosis. 
3.2 LET-7D IS REGULATED BY TGF-β 
3.2.1 FOOTER algorithm predicts a SMAD3 binding site upstream of let-7d 
MicroRNAs have certain similarities to protein coding genes. Most microRNAs are transcribed 
by RNA polymerase II [139], their immediate upstream regions are conserved across species, 
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and they have similar sequence features to protein coding genes in their core promoter regions 
[175]. These observations suggest that the transcriptional mechanism of miRNAs is similar to 
protein coding genes transcribed by RNA polymerase II. Since TGF-β is the main cytokine 
implicated in the pathogenesis of IPF and exerts its actions through the SMAD family of 
transcription factors, we determined whether any of the differentially expressed miRNAs had 
binding sites for SMAD proteins in their upstream regions. We used the FOOTER algorithm 
[169] for this purpose. FOOTER assigns a score to the motif taking into consideration the 
sequence conservation across different species and known binding sites from the TRANSFAC 
database. 
 
Figure 7. Putative SMAD3 binding sites identified by the FOOTER algorithm. 
 
 A SMAD3 binding site was computationally predicted at position -265 from pre-hsa-let-
7d (Fig. 7) using FOOTER. In the figure, the human (HS) and mouse (MM) sequences are 
shown. 
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3.2.2 TGF-β downregulates let-7d in vitro 
To determine whether TGF-β indeed affected the expression of let-7d, we stimulated A549 cells 
in culture with 3 ng/ml of recombinant TGF-β. The expression of hsa-let-7d was significantly 
 
Figure 8. Decreased expression of let-7d on stimulation of A549 cells with TGF-β 
 
reduced (85% decrease) at 2h and 6h post-stimulation (Fig. 8) demonstrating that TGF-β did 
suppress the expression of hsa-let-7d. The results represent an average expression ± S.D. of 
triplicate experiments. These results suggest that TGF-β alters the levels of let-7d either directly 
through binding of one of the SMAD transcription factors to the promoter of let-7d or indirectly 
by acting on an intervening molecule. 
3.2.3 EMSA demonstrates interaction of SMAD3 with the predicted promoter of 
let-7d  
To determine if SMAD3 had an affinity for this predicted binding site in the upstream region of 
let-7d, we performed an electrophoretic mobility shift assay (EMSA). Incubation of target DNA 
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with either recombinant SMAD3 protein (lanes 2, 3 and 4) or nuclear extract of A549 cells (lanes 
5, 6 and 7) revealed distinct bands representing the binding of SMAD3 to the let-7d promoter 
sequence (Fig. 9). The intensity of these bands diminished in the presence of increasing 
 
Figure 9. EMSA demonstrates binding of SMAD3 at the predicted promoter of let-7d. 
 
concentrations of competitor DNA. A supershift was demonstrated by incubating the target DNA 
and nuclear extract in the presence of antibodies to SMAD3 and peroxiredoxin 6. The supershift 
band representing the DNA-protein-antibody complex was visible with SMAD3 antibody but not 
with the control peroxiredoxin 6 antibody. This proved that the SMAD3 binding was specific. 
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3.2.4 Chromatin immunoprecipitation demonstrates SMAD3 binding to the 
predicted promoter in vivo 
SMAD3 ChIP revealed minimal binding of SMAD3 with the let-7d promoter at baseline (lane 1) 
(Fig. 10).  
 
Figure 10. SMAD3 ChIP assay revealed association with let-7d in A549 cells. 
 
A significant band was seen when a SMAD3 immunoprecipitation was performed on 
A549 cells following TGF-β stimulation (lane 2). Lane 3 demonstrates the binding in whole cell 
extract following TGF-β stimulation whereas lane 4 represents a mock immunoprecipitation in 
the presence of anti-Flag antibody.  
3.2.5 SMAD3 is a transcription factor for let-7d   
The promoter activity of the 5' region of let-7d was further analyzed using a luciferase reporter 
assay (Fig. 11). The 1687 base pair region (-1600 to +87) (p-let-7d-luc) and an 8 base pair 
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SMAD3 binding site deletion mutant (p-mlet-7d-luc) were PCR amplified and cloned into the 5' 
end of the luciferase gene. The reporter constructs and empty vector controls were transfected 
into A459 cells with and without TGF-β activation and luciferase activity measured.  
 
Figure 11. Luciferase assay confirms promoter activity of the predicted SMAD3 binding site. 
 
The 1687 base pair region increased the average reporter activity by 25 fold showing that 
this region did have intrinsic promoter activity. Luciferase activity was reduced to less than 30% 
in TGF-β treated cells as compared to untreated controls. This TGF-β mediated inhibition of 
luciferase activity was eliminated when we used the 8 base pair SMAD3 binding site deletion 
mutant. The presented results are representative of at least three experiments. Hence we can 
conclude that SMAD3 is a transcription factor for let-7d and negatively regulates the expression 
of let-7d.  
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3.3 LET-7D AND MIR-30 ARE DOWNREGULATED IN IPF 
TGF-β reduces the expression of let-7d by direct SMAD3 binding to the promoter of let-7d and 
there is abundant active TGF-β signaling in IPF. This explains our finding of decreased let-7d in 
IPF.  
3.3.1 Microarray and real-time PCR demonstrate decreased let-7d and miR-30 
family in IPF lungs 
As mentioned earlier, microRNA microarrays on lung tissues of control subjects and IPF patients 
revealed down-regulation of let-7d and miR-30 family which was subsequently confirmed by 
real-time PCR (Fig. 3 and 4). 
3.3.2 In situ hybridization localizes let-7d and miR-30 to alveolar epithelial cells 
In order to determine the downstream effects of the decrease of these microRNAs in IPF, we 
initially wanted to localize them in the lung. We performed an in situ hybridization on tissue 
microarrays which had 40 IPF tissues and 20 control tissue sections. Staining for let-7d and miR-
30e on lung tissues demonstrated abundant let-7d and miR-30e in control lung sections in 
comparison to IPF. They stained in alveolar epithelial cells (Fig. 12). Panels (i), (iii) and (v) are 
control lungs whereas panels (ii), (iv) and (vi) are IPF lungs.  
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Figure 12. Tissue microarray analysis reveals that let-7d and miR-30e localize within normal alveolar 
epithelium in control lungs and is nearly absent from fibrotic areas in IPF lungs. 
 
Let-7d is localized in alveolar epithelial cells of control lungs as evident by the black 
staining (blue arrows). The black arrows point to areas of dense fibrosis while blue arrows point 
to minimal staining in the immediate surrounding areas. It should be noted that in IPF tissues, 
let-7d and miR-30e does stain in the histologically normal areas but is absent in areas of fibrosis. 
Scale bars in panels (i) and (ii) denote 100 µm while those in (iii), (iv), (v) and (vi) represent 25 
µm.  
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Figure 13. Number of let-7d expressing cells/mm3 was significantly lower in IPF. 
 
The number of let-7d positive alveolar epithelial cells (AECs)/mm2 in 5 fields per case 
was counted by two independent pathologists - observers using the high-resolution DUET, 
Bioview scanning system for CISH morphology and immunocytochemistry applications, at x100 
magnification. Independent t-test and Mann-Whitney test were used to compare let-7d positive 
AECs/mm2 between 40 IPF and 20 control lung samples. There was almost a three-fold reduction 
in let-7d positive cells in the IPF lungs (Fig. 13).  
 
Figure 14. Positive correlation of FVC and let-7d. 
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Lung function studies of these patients show a positive correlation of number of let-7d 
stained cells to the forced vital capacity (FVC) (Fig. 14). FVC is commonly used to define 
severity and to follow the course of patients with IPF. FVC is believed to be a physiologic 
correlate of the extent of fibrosis. The detailed counts per patient with the corresponding FVC 
are included in Appendix B. This indicates that let-7d expression levels can possibly be used as a 
marker for disease progression. 
3.4 HMGA2, A LET-7D TARGET IS UPREGULATED IN IPF 
We found let-7d to be downregulated in IPF lungs and localized it to alveolar epithelial cells. In 
order to determine the mechanism by which this reduction in let-7d contributes to the 
pathogenesis of IPF, we looked for possible targets in the microRNA target database TargetScan 
(www.targetscan.org). HMGA2 and RAS were putative targets of interest. Both HMGA2 and 
RAS are proven direct targets of let-7 microRNAs [176, 177] and both have been shown to have 
a role in EMT in cancers [112, 117, 178]. We initially focused on HMGA2 because it has six let-
7 complementary sites in its 3` UTR. 
3.4.1  Microarray and real-time PCR demonstrate increased HMGA2 in IPF lungs 
Gene expression microarrays on lung tissues of control subjects and IPF patients revealed up-
regulation of HMGA2 which was subsequently confirmed by real-time PCR (Fig 15). 
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Figure 15. HMGA2 is upregulated in IPF by microarray and qRT-PCR. 
 
HMGA2 was expected to be increased in IPF since the inhibition of let-7d on HMGA2 
was decreased. Also, IPF lungs are characterized by a developmental gene signature [10, 11, 13, 
66]. HMGA2 is a developmental gene. It is expressed early during embryogenesis and is silenced 
in adult tissue.  
3.4.2 Immunohistochemistry localizes HMGA2 to alveolar epithelial cells in IPF 
lungs 
Consistent with the results demonstrating downregulation of let-7d in IPF lungs, 
immunohistochemistry revealed expression of HMGA2 in alveolar epithelial cells and in some 
capillary endothelial cells of IPF lungs but not in control lungs.  
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Figure 16. Immunolocalization of HMGA2 in IPF and normal lungs. 
 
In Fig. 16 panels (i) and (ii) show two different IPF lungs demonstrating the immunoreactive 
protein primarily in alveolar epithelial cells, either in cytoplasm or nuclei (black arrows). The red 
arrows in (i) point to collapsed air spaces which are lined by HMGA2 positive epithelial cells. 
Panel (iii) shows nuclear staining of HMGA2 in elongated epithelial cells (asterisk indicates an 
alveolar space) and some fibroblast-like cells immersed in a fibroblastic focus. Positive 
endothelial cells are marked with red arrows. Normal lungs in panel (iv) were negative for 
HMGA2. The scale bars in all panels denote 100 µm. 
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3.5 INHIBITION OF LET-7D RESULTS IN INCREASED HMGA2 EXPRESSION 
Let-7 microRNAs have been previously shown to downregulate HMGA2 [176], a mediator of 
TGF-β-induced EMT [112]. Considering that we found downregulation of let-7d and 
concomitant upregulation of HMGA2 in IPF lungs we explored whether TGF-β induced 
HMGA2 and whether let-7d was a regulator of HMGA2 expression in lung epithelial cell lines. 
3.5.1 TGF-β induces HMGA2 expression 
As mentioned ealier, stimulation of A549 cells by TGF-β caused a dramatic reduction in levels 
of let-7d at 2h and 6h post-stimulation. Since the let-7 family targets HMGA2 [176], we 
expected a corresponding increase in HMGA2. Stimulation of A549 cells by TGF-β did lead to a 
significant increase in HMGA2 (p<0.05) (Fig 17).    
 
Figure 17. TGF-β increases HMGA2 expression. 
 53 
3.5.2 HMGA2 is a target of let-7d in a lung epithelial cell line 
The let-7 family was shown to target HMGA2 in a variety of cells but not in a lung epithelial cell 
line. Before determining the functional role of the increase in HMGA2 we verified that HMGA2 
is targeted by let-7d also in a lung epithelial cell line. Transfection of A549 cells with a let-7d 
inhibitor for 24h and 48h led to a significant increase in HMGA2 at 24h that remained elevated 
at 48h. 
 
Figure 18. Inhibition of let-7d causes an increase in HMGA2. 
3.5.3 let-7d prevents TGF-β induced increase in HMGA2 
TGF-β reduces let-7d levels through SMAD3 and let-7d in turn reduces HMGA2. Thuault et al. 
[112] demonstrated that TGF-β also increases HMGA2 by direct binding of SMAD4 to the 
promoter of HMGA2. Overexpression of let-7d in RLE-6TN cells by transfection with pre-let-7d 
prevented the TGF-β induction of HMGA2. 
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Figure 19. let-7d prevents TGF-β-mediated increase in HMGA2. 
 
These results demonstrate that let-7d is a regulator of HMGA2 expression in lung 
epithelial cell lines and that the increase in HMGA2 after TGF-β stimulation is in part dependent 
on inhibition of let-7d by TGF-β.  
3.6 INHIBITION OF LET-7D RESULTS IN EMT 
Since let-7d targets HMGA2 a known mediator of TGF-β-induced EMT [112], we evaluated 
whether altering let-7d levels induces EMT in vitro. 
3.6.1 Real time PCR demonstrates an increase in mesenchymal markers following 
inhibition of let-7d 
We inhibited let-7d in A549 cell line, RLE-6TN cell line and primary normal human bronchial 
epithelial (NHBE) cells. Levels of the mesenchymal markers alpha-smooth muscle actin 
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(ACTA2), vimentin (VIM) and N-cadherin (CDH2) were measures at 48h post-transfection. All 
three markers were significantly increased in both A549 and RLE-6TN cell lines. VIM and 
ACTA2 increased but CDH2 remained unchanged in primary NHBE cells.  
 
 
Figure 20. Inhibition of let-7d results in increased mesenchymal markers in (A) A549 cell line, (B) 
RLE-6TN cell line and (C) NHBE primary cells. 
3.6.2 Immunofluorescence and immunoblotting reveals increase in mesenchymal 
markers and decrease in epithelial markers following inhibition of let-7d 
Immunofluorescence confirmed the results at the protein level (Fig 21). A549 cells transfected 
with a let-7d inhibitor stained positive (red) for CDH2, VIM and ACTA2 48 h post-transfection, 
while mock-transfected cells did not express positive staining. The green fluorescence represents 
cytokeratin, an epithelial marker. The red fluorescence denotes the mesenchymal markers 
(CDH2, VIM and ACTA2). Nuclei were counterstained with DAPI. While red staining is 
observed in cells transfected with let-7d inhibitor (right panel), there is no staining in cells 
transfected with a control oligonucleotide (left panel). 
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Figure 21. Inhibition of let-7d demonstrates an increase in mesenchymal proteins in A549 cells. 
 
RLE-6TN cells transfected with a let-7d inhibitor for 72h show increase expression of 
mesenchymal markers ACTA2 and VIM and decrease in epithelial markers cytokeratin and TJP1 
(Fig. 21) by immunoblotting suggestive of EMT. 
3.6.3 Let-7d-induced EMT is not totally dependent on HMGA2 
To determine if the EMT seen after inhibiting let-7d is due to the corresponding increase in 
HMGA2, we inhibited both let-7d and HMGA2 simultaneously. As seen in Fig. 22, the 
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mesenchymal markers increased after let-7d inhibition but though CDH2 returned to baseline 
after simultaneous inhibition of HMGA2, ACTA2 and VIM remained elevated. 
 
Figure 22. EMT caused by reduced let-7d is not totally dependent on HMGA2. 
 
A possible explanation for this phenomenon could be that let-7d targets other fibrosis-
relevant genes along with HMGA2. These genes maintain the mesenchymal phenotype 
irrespective of a change in HMGA2. A second possibility is that let-7d along with a few other 
microRNAs may be targeting HMGA2 together. For example, miR-17, miR92 and miR-26 are 
all predicted to target HMGA2. Also, we found that miR-30 inhibition increase HMGA2 which 
is discussed in the next section. Hence HMGA2 may be a direct target of miR-30 but this needs 
to be proven.   
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3.7 INHIBITION OF MIR-30 FAMILY 
There are 5 members in the miR-30 family- miR-30a through miR-30e, all being 
downregulated in IPF. To perform functional studies, it would have been quite toxic to the cells 
to transfect them with five different inhibitors, one for each member. To overcome this problem 
we designed an inhibitor which could inhibit three members miR-30a, miR-30d and miR-30e 
that have similar sequences than the other two members. We adapted the design from Mott et al. 
[179]. We designed a locked nucleic acid (LNA)/DNA oligonucleotide. Based on sequence 
identity within the family, LNA bases were positioned at bases shared by all family members.  
Eight LNA residues were placed into two blocks of four. In the figure below, the LNA bases are 
marked in red.  
 
 
Figure 23. Inhibition of miR-30 members by a single oligonucleotide. 
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 As seen in the figure above, transfection of 50nM of this oligonucleotide, totally 
knocked down the three members. RNA isolated 24h and 48h after transfection revealed an 
increase in HMGA2, VIM, EDNRA and ADAM19. All these genes are increased in IPF and/or 
EMT. Jain et al . showed that endothelin-1 induces alveolar EMT through endothelin type A 
receptor (EDNRA)-mediated production of TGF-β1 [54].  We chose to test expression of VIM, 
EDNRA and ADAM19 because they are predicted targets of the miR-30 family by TargetScan.  
 
 
Figure 24. Inhibition of miR-30 results in increase in genes upregulated in IPF. 
 
Two members of the miR-30 family, miR-30c and miR-30e are in the intron of nuclear 
transcription factor Y, gamma (NFYC). NFYC represses Smad2 and Smad3 transactivating 
activity either by direct binding to the Smad-responsive element or through their association with 
the Smad-interacting transcription factor FAST-2 (forkhead activin signal transducer-2) [180]. 
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Figure 25. miR-30c and miR-30e are in the intron of NFYC. 
 
Generally intronic microRNAs are transcribed with their host genes in which case, NFYC 
should also be downregulated in IPF. We did find NFYC to be decreased in IPF by microarrays 
and real-time PCR highly suggestive of cotranscription of NFYC, miR-30e and miR-30c but this 
needs to be proven by transcriptional gene silencing of NFYC. 
 
Figure 26. NFYC is down-regulated in IPF. 
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3.8 INHIBITION OF LET-7D IN VIVO 
3.8.1 Dosage optimization 
In vitro inhibition of let-7d led to EMT in A549 and RLE-6TN cell lines and NHBE primary 
cells. To determine the effects of let-7d inhibition in-vivo we administered the let-7d antagomir 
designed as previously described [173]. Initially we administered the antagomir at a dose of 80 
mg/kg body weight to mice. This dose was very toxic which caused death of two of the four 
mice. The two remaining mice were very sick and were sacrificed after a single dose. Their lungs 
were grossly hemorrhagic. This single dose was enough to knock down let-7d totally. We 
reduced the dose to 10 mg/kg body weight and administered it intratracheally into the lungs of 4 
mice on three consecutive days and sacrificed the mice on the fourth day. At this dose too the 
mice appeared sick and the lungs were hemorrhagic and it was impossible to maintain them 
longer. To better observe the long term effects of let-7d inhibition we reduced the dose to 5 
mg/kg body weight and treated the animals for 17 days. The antagomir was given on days 1, 2, 3, 
8, 9, 10, 15, 16 and 17. At this dose we detected a significant decrease in let-7d in the lung (Fig. 
27) but the mice did not demonstrate any discomfort. Control mice were administered an equal 
volume of saline. 
3.8.2 Knockdown of let-7d 
The intratracheal administration of the let-7d antagomir caused a complete knockdown of let-7d 
in the lung with all the three doses viz. 80, 10 and 5 mg/kg (Fig. 27).  
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Figure 27. Knockdown of let-7d by the antagomir at different doses. 
 
After we optimized the dose to 5 mg/kg body weight, we designed a scrambled 
oligonucleotide control. This scrambled control had four mismatches in the sequence but was 
identical to the antagomir in terms of the base modifications. Let-7d was knocked down 
significantly using the antagomir in comparison to the scrambled oligonucleotide. 
 
Figure 28. Knockdown of let-7d by the antagomir in comparison to the scrambled control. 
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3.8.3 Profibrotic changes after let-7d inhibition in vivo 
3.8.3.1 In comparison to saline control 
We assessed the degree to which we were able to induce EMT in the mice lungs after 
administering 10 mg/kg antagomir for 3 days. Let-7d inhibition caused a significant decrease in 
the expression of the epithelial markers CDH1 and ZO-1 and a significant increase in COL1A1 
and HMGA2 expression in the lung (Fig. 29).  
 
Figure 29. Reduced epithelial markers and increased mesenchymal markers following antagomir 
administration. 
 
In the extended protocol, in which the mice were treated for 17 days, we observed an 
increase in collagen and ACTA2 by Masson’s trichrome and immunohistochemistry 
respectively. Masson’s trichrome stain of formalin fixed mouse lung demonstrated increased 
thickening of alveolar septa and increased blue stain (red arrows) indicative of the presence of 
collagen in let-7d antagomir-treated lungs (Fig. 30A). Panels (i), (iii) are saline lungs and panels 
(ii), (iv) are antagomir-treated lungs. The scale bars in (i) and (iii) denote 100 µm and those in 
(ii) and (iv) denote 25 µm. Quantitation of the blue stain revealed a 2.6 fold increase in 
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antagomir-treated lungs (Fig. 30C). Morphometric analysis showed that in the antagomir-treated 
lungs, the total tissue per field was increased by 21% relative to the control sections (Fig. 30B). 
For these quantitations, we selected images without airways and blood vessels to avoid any bias. 
 
Figure 30. Masson trichrome staining after 18 days of saline or antagomir treatment. 
 
Immunohistochemical staining for ACTA2 revealed enhanced immunoreactive protein 
(brown) in alveolar walls in antagomir-treated mice lungs that was not observed in saline treated 
mice (Fig. 31). Panels (i), (iii) are saline lungs and panels (ii), (iv) are antagomir-treated lungs. 
The scale bars in (i) and (iii) denote 100 µm and those in (ii) and (iv) denote 25 µm. Manual 
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counting of the ACTA2-positive cells revealed a significant increase in the antagomir-treated 
lungs. 
 
 
Figure 31. Immunolocalization of α-smooth muscle actin after 18 days of saline or antagomir 
treatment. 
3.8.3.2 In comparison to the scrambled oligonucleotide  
We repeated the same extended protocol of treating the mice for 17 days but used the 
scrambled oligonucleotide this time to control for any changes caused by introduction of the 
oligonucleotide itself. We observed and increase in collagen, ACTA2 and CDH2 in the 
antagomir-treated lungs but VIM and fibroblast specific protein 1 (FSP1) were unchanged by 
real-time PCR. 
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Figure 32. Increase in mesenchymal markers following antagomir administration. 
 
Since RAS is a known direct target of let-7 family of microRNAs, we used KRAS as a 
positive control. Immunohistochemistry for KRAS showed increased staining for KRAS in 
alveolar epithelial cells and macrophages as demonstrated by the positive brown stain (Fig. 33).  
 
Figure 33. Increase in RAS in antagomir lungs. 
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Masson trichrome staining for collagen shows increased blue staining for collagen in 
antagomir lungs and thickening of alveolar septae (Fig. 34). 
 
Figure 34. Increase in collagen in antagomir lungs. 
 
Immuhistochemical staining for ACTA2 and CDH2 both show increased brown staining 
in antagomir treated lungs but these changes were more focal and seen in certain areas of the 
lung sections (Fig. 35, 36). 
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Figure 35. Increase in ACTA2 in antagomir lungs. 
 
Figure 36. Increase in CDH2 in antagomir lungs. 
 
To demonstrate EMT in the antagomir treated lungs, we colocalized an alveolar epithelial 
marker, surfactant protein C (SPC) with the mesenchymal markers, FSP1 and ACTA2 by 
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immunofluorescence (Fig. 37). During the process of EMT, the alveolar epithelial cells gradually 
lose the epithelial markers and gain mesenchymal markers but during a brief period express both. 
The white arrows point to cells expressing both markers. The red arrows point to cells expressing 
only SPC indicating that there are some cells which have still not undergone EMT. 
 
Figure 37. Colocalization of FSP1 and ACTA2 with SPC in antagomir lungs. 
 70 
Fig. 37 shows the relative average colocalization of epithelial and mesenchymal markers 
in five different fields of each slide. For the specific images shown in the figure, there was 38% 
and 41% colocalization of the total tissue for FSP1 and ACTA2 respectively. The scrambled 
control sections however showed only about 6% colocalized area per section. 
Taken together these results suggest that in-vivo inhibition of let-7d in the lung causes 
changes consistent with changes in epithelial cell phenotype (decrease in CDH1 and ZO1) and 
consistent with early fibrosis (thickened alveolar septa, increased collagen, ACTA2 and CDH2). 
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4.0  DISCUSSION 
In this study we explored the expression, regulation and potential role of microRNAs in 
IPF. Among the downregulated microRNAs in IPF lungs we focused on let-7d and discovered 
that it was directly transcriptionally inhibited by the key pro-fibrotic cytokine TGF-β. In-vitro 
inhibition of let-7d induced an increase in mesenchymal markers and a corresponding decrease 
in epithelial markers in lung epithelial cell lines suggestive of EMT. In-vivo inhibition of let-7d 
in mouse lungs caused alveolar septal thickening, decreased expression of epithelial markers and 
increase in collagen, ACTA2 and CDH2 consistent with early fibrotic changes. We demonstrated 
EMT by colocalizing FSP1 and ACTA2 with the epithelial marker SPC. In IPF lungs let-7d 
expression was drastically diminished, while HMGA2 expression was increased in alveolar 
epithelial cells. Increased expression of HMGA2 was induced by let-7d inhibition in-vitro and 
TGF-β induced expression of HMGA2 was inhibited by let-7d expression suggesting that the 
concomitant decrease in let-7d and increase in HMGA2 in human lungs were associated. Taken 
together our findings suggest that let-7d inhibition is a key regulatory event in the dramatic 
phenotypic changes that happen in the alveolar epithelium in IPF.  
In this study we demonstrate the influence of TGF-β, the key profibrotic cytokine and a 
regulator of EMT [181] on the expression of a microRNA through direct effect on its promoter. 
This result is consistent with the recent genome scale analysis of microRNA promoters and 
evidence for binding by stem cell transcription factors as well as RNA polymerase II that suggest 
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that the expression of many microRNAs is under dynamic transcriptional regulation by 
transcription factors [182, 183]. So far changes in let-7 microRNAs expression levels have been 
mostly attributed to their localization to fragile sites [184] to post-transcriptional modification 
[185] or to epigenetic changes [143]. Our discovery that let-7d is directly inhibited by TGF-β 
adds a new potential mechanism for regulation of microRNAs and may have important 
therapeutic implication as inhibitors of TGF-β signaling and activation are currently evaluated 
for cancer and fibrosis. Furthermore, the suggestion that some of TGF-β effects on epithelial 
cells may be mediated through microRNAs may have significant implications in better 
understanding the profound and sustained effects of TGF-β on cell and organ phenotype. 
4.1 LET-7 FAMILY ALSO TARGETS OTHER FIBROSIS RELEVANT GENES  
The let-7 family of microRNAs was one of the first discovered [136] and the most 
extensively studied; however this is the first time a member of the let-7 family has been 
implicated in a non-tumor disease. Members of the let-7 family are temporally regulated 
microRNAs which coordinate developmental timing [136]. They are considered tumor 
suppressors, regulating RAS and many cell cycle genes [186] and their expression is supposed to 
sustain an “epithelial” gene signature [187]. Among the genes suppressed by the let-7 family is 
HMGA2, a structural transcriptional regulator expressed in early embryonic development, some 
benign tumors and lung cancer [176]. In the context of IPF it is of interest to note that HMGA2 
confers a growth advantage to fibroblasts as evident by the retarded growth in hmga2-deficient 
mouse embryonic fibroblasts compared to wild-type fibroblasts [188] and is also a mediator of 
TGF-β induced EMT [112]. However, while we found a dramatic decrease in let-7d expression 
 73 
accompanied by an increased in HMGA2 in human IPF lungs, and demonstrated that inhibition 
of let-7d leads to EMT in-vitro and to early fibrotic changes in-vivo, we do not have direct 
evidence that this effect is solely mediated through HMGA2. As seen in Fig. 22, the 
mesenchymal markers increased after let-7d inhibition but though CDH2 returned to baseline 
after simultaneous inhibition of HMGA2, ACTA2 and VIM remained elevated. 
A more realistic interpretation at this stage would be that in the lung, downregulation of 
let-7d leads to upregulation of HMGA2 as well as other fibrosis relevant targets of let-7 such as 
RAS, IGF1, IGF1R (Fig. 38) [178] and thus leads to the profound and sustained changes in 
cellular phenotype that are indeed observed in IPF.  
 
Figure 38. Overlapping targets of microRNAs down-regulated in IPF. 
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Fig. 38 depicts the computationally predicted targets of the microRNAs down regulated 
in our IPF dataset. These fibrosis-relevant and EMT-relevant targets and the predicted sites of 
each miRNA in their 3’ UTRs were chosen from TargetScan database. The fact that let-7 
inhibition is sufficient to induce changes consistent with EMT in-vitro and expression of 
mesenchymal markers as well as thickening of alveolar septum indicative of early fibrosis in-
vivo also suggests an effect mediated through modification of the expression of multiple fibrosis 
relevant genes and not just a single gene. 
It is important to note that while we focus on let-7d, the downstream effects of let-7d 
overexpression or inhibition are probably common to all members of the let-7 family of 
microRNAs.  
 
Figure 39. Specificity of the let-7 inhibitor used in vitro and in vivo. 
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While the inhibitory effects we describe do not go through microRNAs that are not members of 
the let-7 family it is highly unlikely that this effect will be mediated only through let-7d and not 
through other members of the family. As seen in the figure above, the let-7d inhibitor used in 
vitro (upper panel) or the antagomir used in vivo (lower panel) also inhibited a member of the 
same family, let-7c, but not miR-10a or miR-19a, two randomly selected microRNAs. 
4.2 ROLE OF OTHER MICRORNAS 
Our results add to previous results that implicated a role for inhibition of microRNAs in EMT 
[120-123]. The miR-200 family prevents EMT by targeting the transcription factors ZEB1 and 
SIP1 that repress E-cadherin, an epithelial cell marker [120-123]. Similar to let-7d, TGF-β 
stimulation also decreased expression of the miR-200 family. Overexpression of the miR-200 
family could not completely block EMT [121] suggesting that let-7d and miR-200 family may be 
acting synergistically possibly with a few other microRNAs in preventing EMT. While the 
current study does not directly overlap the putative pathway of miR-200 family, there is no doubt 
that there may be multiple signaling cascades likely to be at work in a complex cellular transition 
such as EMT.  
Inhibition of miR-30 family members led to an increase in VIM, ADAM19, HMGA2 and 
EDNRA. They may be direct targets of miR-30 which needs to be proven by 3` UTR reporter 
assays. Of particular interest are EDNRA and connective tissue growth factor (CTGF). It has 
been shown that endothelin-1 is an important mediator of EMT in alveolar epithelial cells, acting 
through EDNRA–mediated TGF-β production [54]. Connective tissue growth factor (CTGF) is a 
known target of miR-30 [189]. CTGF is a growth and chemotactic factor for fibroblasts encoded 
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by an immediate early gene that is transcriptionally activated by TGF-β [190]. It is induced by a 
number of profibrotic mediators and localizes to proliferating type II alveolar epithelial cells and 
activated fibroblasts [191]. CTGF is a proven target of miR-30 and has an important role in the 
control of structural changes in the extracellular matrix of the myocardium [189]. 
On the basis of studies on endothelin, miR-200 and from our data, it is highly likely that 
let-7d, miR-30 and miR-200 act synergistically to maintain the epithelial cell phenotype. 
4.3 MICRORNA EXPRESSIONS SIMILAR TO THOSE IN IPF 
Microarray analysis identified an IPF specific gene expression signature characterized by the up-
regulation of genes indicative of active tissue remodeling, including extracellular matrix and a 
large number of myofibroblast/smooth muscle cell–associated and epithelial cell–related genes 
[6, 8, 11, 13]. IPF lungs are also enriched with genes associated with lung development, 
indicating that embryonic signaling pathways involved in epithelial cell plasticity may be 
aberrantly activated [8, 11, 13, 66]. It is possible that as genes in different organs or during 
different embryonic stages maintain the epithelial cell phenotype, microRNAs have a similar 
role. We found that most of the microRNAs downregulated in IPF were also downregulated in 
fetal lung tissues as assessed by real-time PCR (Fig. 6).  
The microRNA profiling of rat lungs exposed to cigarette smoke for 28 days revealed a 
decrease in the let-7 family, miR-26 and miR-30 families [192]. These microRNAs are also 
decreased in IPF which has smoking as one of the risk factors for the disease. Schembri et al . 
studied the bronchial airway microRNA expression of smokers and non-smokers. Members of 
the miR-17 ~ 92 cluster and miR-30a were downregulated in smokers [193]. The let-7 family, 
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miR-30, miR-26 families are downregulated in many cancers [194-201] .This suggests that the 
microRNA signature of EMT is similar irrespective of the pathological or physiological 
condition being studied such as development, environmental factors like smoking or diseases 
like IPF and cancer. 
4.4 PROPOSED MODEL 
On the basis of our data and what is published in literature, we propose a model for EMT in IPF 
(Fig. 40). After the initial and persistent injury to the alveolar epithelial cell, there is an influx of 
cytokines like TGF-β, ΕΤ−1 and CTGF. One of the reasons for the increase in ET-1 and CTGF 
could be the reduction in miR-30. TGF-β synthesis is increased by ET-1 and vice versa. Increase 
in TGF-β phosphorylates the SMADs. SMAD3 transcriptionally inhibits let-7d which in turn 
negatively regulates HMGA2, RAS and possibly IGF1 and IGF1R. NFYC tries to maintain 
homeostasis by binding to the SMAD responsive element and suppresses SMAD3 activity. 
SMAD4 increases transcription of HMGA2 whereas SMAD3 and HMGA2 co-operatively 
increase SNAI1 transcription. TGF-β inhibits the ID molecules which in turn prevent down-
regulation of CDH1 by preventing the E2A transcription factors from binding to the CDH1 
promoter. The targets of let-7 viz. HMGA2, RAS, IGF, IGF1R increase the transcription factors 
SNAI1, SNAI2, TWIST and ZEB1. These inhibit CDH1 and other targets ultimately leading to 
EMT. 
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Figure 40. Model for EMT in IPF. 
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5.0  CONCLUDING REMARKS 
5.1 SUMMARY 
In summary, we demonstrate that IPF lungs are different from control lungs in their microRNA 
repertoire. We discovered that let-7d, a microRNA significantly downregulated in IPF, is 
negatively transcriptionally regulated by TGF-β. Furthermore, inhibition of let-7d alone is 
sufficient to cause EMT changes in A549, RLE-6TN cells and NHBE cells. Concomitant with 
let-7d down-regulation in IPF lungs, we found significant increases in lung expression of 
HMGA2 suggesting that let-7 inhibition of HMGA2 is released in IPF lungs. Finally, we 
demonstrate that let-7 inhibition in-vivo in the lung may cause changes in the lung alveolar 
epithelium with increases in mesenchymal markers, decreases in epithelial markers and 
thickening of alveolar septa. The discovery of the downregulation of let-7d in IPF, its regulation 
by TGF-β and its potential role in EMT and fibrosis may have important implications in our 
understanding of the molecular mechanisms underlying IPF as well lead to the development of 
new therapeutic interventions in this devastating and incurable disease. 
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5.2 FUTURE DIRECTIONS 
Elucidation of the mechanism and pathway through which let-7d exerts its action in inducing 
EMT is essential. Additionally, this study is not complete until a therapeutic role for let-7 is 
established. 
Inhibition of HMGA2 was not enough to stop EMT which suggests that let-7d may be 
exerting its effects by acting on a number of IPF-relevant targets which include RAS, IGF1, 
IGF1R and possibly a few others. The possibility that let-7d could be targeting these other genes 
needs to be explored. A few microRNAs decreased in IPF have common targets. For example, 
HMGA2 is a computationally predicted target of miR-17, miR-26 and miR-92 and could 
possibly be a direct target of miR-30 which needs to be proven by a reporter assay. Repeating the 
in vitro experiments with inhibition of all or a combination of these microRNAs will be 
beneficial.  
Finally, a few in vivo experiments in mice are warranted. First, using transgenic mice like 
HMGA2 or RAS knockouts will help to dissect the pathway through which reduction in let-7d 
causes EMT. Secondly, administration of the let-7d antagomir intravenously will reinforce the 
fact that let-7d reduction leads to EMT in other organs as well such as the kidney in which EMT 
is well-studied. Lastly, resolution of fibrosis by administration of a let-7d mimic to mice having 
bleomycin-induced lung fibrosis will establish a therapeutic role for let-7d. 
 
 
 81 
APPENDIX A 
LIST OF ANTIBODIES  
Table 2. List of antibodies used for immunoblotting and their relative concentrations. 
Antibody Type Company Concentration 
ACTA2 rabbit monoclonal Abcam 1:20000 
VIM mouse monoclonal Abcam 1:100 
cytokeratin rabbit polyclonal Abcam 1:1000 
actin mouse monoclonal Sigma 1:4000 
laminin A/C rabbit polyclonal Santa Cruz 1:1000 
TJP1 rabbit polyclonal Santa Cruz 1:500 
 
Table 3. List of antibodies used for immunofluorescence and their relative concentrations. 
Antibody Type Company Concentration 
CDH2 rabbit polyclonal Abcam 1:500 
VIM mouse monoclonal Abcam 1:1000 
ACTA2 rabbit monoclonal Abcam 1:600 
cytokeratin mouse monoclonal Abcam 1:500 
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SPC rabbit polyclonal Abcam 1:600 
FSP1 rabbit polyclonal Abcam 1:600 
HMGA2 rabbit polyclonal Abcam 1:50 
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APPENDIX B 
ISH DATA WITH FVC 
Table 4. let-7d counts of in situ hybridization and corresponding forced vital capacities. 
case Diagnosis let-7d positive AECs/mm2 FVC (% pred) 
1 IPF 16 59 
2 IPF 16 60 
3 IPF 10 51 
4 IPF 10 48 
5 IPF 16 58 
6 IPF 26 60 
7 IPF 25 59 
8 IPF 20 65 
9 IPF 15 50 
10 IPF 20 55 
11 IPF 5 51 
12 IPF 2 48 
13 IPF 20 55 
14 IPF 40 81 
15 IPF 30 66 
16 IPF 28 62 
17 IPF 17 60 
18 IPF 21 56 
19 IPF 33 70 
20 IPF 31 65 
21 IPF 19 63 
22 IPF 14 59 
23 IPF 13 54 
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24 IPF 15 50 
25 IPF 8 53 
26 IPF 7 55 
27 IPF 20 56 
28 IPF 18 48 
29 IPF 12 43 
30 IPF 27 61 
31 IPF 10 67 
32 IPF 9 49 
33 IPF 17 48 
34 IPF 15 56 
35 IPF 14 67 
36 IPF 18 52 
37 IPF 22 54 
38 IPF 15 49 
39 IPF 16  
40 IPF 25  
41 Control 55  
42 Control 58  
43 Control 48  
44 Control 65  
45 Control 77  
46 Control 55  
47 Control 65  
48 Control 47  
49 Control 61  
50 Control 59  
51 Control 65  
52 Control 58  
53 Control 82  
54 Control 44  
55 Control 46  
56 Control 24  
57 Control 28  
58 Control 84  
59 Control 80  
60 Control 75  
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